This legislation aims to enhance access to certain drugs and biological products for patients, particularly those covered by Medicare, by instituting a rebate system for selected medications that are subject to price negotiations. The primary goal is to make these drugs more affordable, thereby reducing out-of-pocket expenses for patients. Key provisions include the establishment of a formal rebate requirement for selected drugs, mandating manufacturers to report sales and pricing information to the Secretary of Health and Human Services.